{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:01:44Z","timestamp":1776430904604,"version":"3.51.2"},"reference-count":22,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>The International Bladder Cancer Group (IBCG) has proposed a prognostic model for intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) for clinical decision-making. We applied the IBCG IR model in a population-based Swedish setting in patients with primary IR NMIBC diagnosed 2013\u20132014 in BladderBaSe 2.0. Patients were stratified into low-risk (unifocal and tumour size &lt; 3 cm) and intermediate-risk (multiple and\/or tumour size \u2265 3 cm) for estimation of 1- and 3-year recurrence-free survival (RFS). Among 710 patients with IR NMIBC, 329 (46%) and 381 (54%) were categorized as low- and intermediate-risk, respectively. Probabilities of disease recurrence or death at 1 and 3 years in low-risk patients were 19% (95% confidence interval [CI]: 15\u201323) and 41% (95% CI: 35\u201346), versus 27% (95% CI: 22\u201331) and 45% (95% CI: 40\u201350) in the intermediate-risk group. In a sensitivity analysis including only patients receiving serial adjuvant instillations (n = 152) the corresponding probabilities at 1 and 3 years were 19% (95% CI: 10\u201328) and 33% (95% CI: 22\u201343) versus 15% (95% CI: 7\u201323) and 31% (95% CI: 20\u201341), respectively. Thus, no clinically meaningful difference in recurrence-free survival was observed between International Bladder Cancer Group low- and intermediate-risk groups in this population-based primary non-muscle invasive bladder cancer setting.<\/jats:p>","DOI":"10.2340\/sju.v61.45712","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:22:37Z","timestamp":1776428557000},"page":"127-130","source":"Crossref","is-referenced-by-count":0,"title":["Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer"],"prefix":"10.2340","volume":"61","author":[{"given":"Denis","family":"Mesinovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Bobjer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskar","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"Aljabery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truls","family":"G\u00e5rdmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staffan","family":"Jahnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Jerlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Kj\u00f6lhede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Uno","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viveka","family":"Str\u00f6ck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"S\u00f6derkvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Ull\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"150439","doi-asserted-by":"crossref","unstructured":"Tan WS, Steinberg G, Witjes JA, et al. Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022;5(5):505\u2013516.","DOI":"10.1016\/j.euo.2022.05.005"},{"key":"150440","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euo.2022.05.005","DOI":"10.1016\/j.euo.2022.05.005"},{"key":"150441","doi-asserted-by":"crossref","unstructured":"Soria F, Rosazza M, Livoti S, et al. Clinical validation of the intermediate-risk non-muscle-invasive bladder cancer scoring system and substratification model proposed by the International Bladder Cancer Group: a multicenter young academic urologists urothelial working group collaboration. Eur Urol Oncol. 2024;7(6):1497\u20131503.","DOI":"10.1016\/j.euo.2024.06.004"},{"key":"150442","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euo.2024.06.004","DOI":"10.1016\/j.euo.2024.06.004"},{"key":"150443","doi-asserted-by":"crossref","unstructured":"Li R, Hensley PJ, Babjuk M, et al. Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. Eur Urol Oncol. 2025;8(6):1685-1695.","DOI":"10.1016\/j.euo.2025.08.003"},{"key":"150444","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euo.2025.08.003","DOI":"10.1016\/j.euo.2025.08.003"},{"key":"150445","doi-asserted-by":"crossref","unstructured":"Zaurito P, Scilipoti P, Longoni M, et al. The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancer. BJU Int. 2026;137(1):201-208.","DOI":"10.1111\/bju.16905"},{"key":"150446","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.16905","DOI":"10.1111\/bju.16905"},{"key":"150447","doi-asserted-by":"crossref","unstructured":"Busch C, Algaba F. The WHO\/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch. 2002;441(2):105-108.","DOI":"10.1007\/s00428-002-0633-x"},{"key":"150448","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00428-002-0633-x","DOI":"10.1007\/s00428-002-0633-x"},{"key":"150449","doi-asserted-by":"crossref","unstructured":"H\u00e4ggstr\u00f6m C, Hagberg O, G\u00e5rdmark T, et al. Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0. BMJ Open. 2022;12(12):e064898.","DOI":"10.1136\/bmjopen-2022-064898"},{"key":"150450","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064898","DOI":"10.1136\/bmjopen-2022-064898"},{"key":"150451","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V, et al. European Association of Urology (EAU) prognostic factor risk groups for Non-muscle-invasive Bladder Cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79(4):480\u2013488.","DOI":"10.1016\/j.eururo.2020.12.033"},{"key":"150452","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2020.12.033","DOI":"10.1016\/j.eururo.2020.12.033"},{"key":"150453","doi-asserted-by":"crossref","unstructured":"Contieri R, Martini A, Beijert IJ, et al. Towards defining follow-up strategies for patients with primary intermediate-risk non-muscle-invasive bladder cancer. Eur Urol Oncol. 2025;8(4):977\u2013985.","DOI":"10.1016\/j.euo.2025.04.010"},{"key":"150454","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.010","DOI":"10.1016\/j.euo.2025.04.010"},{"key":"150455","doi-asserted-by":"crossref","unstructured":"Jahnson S, Jancke G, Olsson H, Aljabery F. Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications. BJU Int. 2023;132(6):656\u2013663.","DOI":"10.1111\/bju.16100"},{"key":"150456","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.16100","DOI":"10.1111\/bju.16100"},{"key":"150457","doi-asserted-by":"crossref","unstructured":"van Rhijn BWG, Hentschel AE, Br\u00fcndl J, et al. Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary Ta\/T1 non-muscle-invasive bladder cancer: a Multicenter European Association of Urology non-muscle-invasive bladder cancer guidelines panel study. Eur Urol Oncol. 2021;4(2):182\u2013191.","DOI":"10.1016\/j.euo.2021.06.002"},{"key":"150458","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euo.2020.12.002","DOI":"10.1016\/j.euo.2020.12.002"},{"key":"150459","unstructured":"Kwong JCC, Al-Daqqaq Z, Chelliahpillai Y, et al. Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004\/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer. Eur Urol. Published online October 7, 2025."},{"key":"150460","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4145","DOI":"10.1016\/j.eururo.2025.09.4145"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45712\/53558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45712\/53558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:22:46Z","timestamp":1776428566000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/45712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":22,"URL":"https:\/\/doi.org\/10.2340\/sju.v61.45712","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}